Investing
See our most recent company presentation to learn more about investing in PharmAla Biotech.
Company overview
We are a Canadian biotechnology company dedicated to the domestic research & development and sourcing of clinical-grade LaNeo™ MDMA and novel MDXX compounds in service to the scientific research community and commercial use in select jurisdictions.
Recent regulatory changes in the US have given “Breakthrough” status to treatments based on MDMA. MDMA is currently being investigated for the treatment of a number of disorders.
Market background
The Psychedelics market in the US is growing with a CAGR of 16% in the forecast period of 2020 to 2027 and is expected to reach US$ 6.9B by 2027 from US$ 2.1B in 2019.
Growing acceptance of psychedelic drugs within clinical settings are factors for the market growth. Psychedelic drugs are used to enhance or change sensory perceptions, energy levels, thought processes, and to facilitate spiritual experiences.
Intellectual Property
PharmAla’s Intellectual Property provides vertical integration of MDXX compound Chemistry, Manufacturing and Control (CMC)
01
Novel Chemical Entities
02
Novel Synthesis Processes
03
Full scale process development
04
Formulation and Drug Product IP
| Patents | Submitted |
|---|---|
| 2 Novel MDXX synthesis routes | Q2 2021 |
| Provisional patent on 2 Novel MDXX Entities | Q3 2021 |
| 3 Additional Molecules in Drug Pipeline | Q1 2022 |
Swipe the table to see more.
We want to ensure the future of clinical MDMA research in Canada. Join us.
MDMA is under evaluation as a potential treatment for couples therapy, eating disorders, alcohol addiction, anxiety and depression.
PharmAla Biotech is committed to becoming Canada’s first and leading supplier of clinical-grade LaNeo™ MDMA for research purposes.
MDMA Facts
What is it?
MDMA – or 3,4- methylenedioxymethamphetamine – is a synthetically-derived psychoactive substance classified as an empathogen. It is not the same as the street drug ecstasy.
Where did it come from?
Originally synthesized in the early 1900s by Merck, MDMA became more commonly used in the 1970s and early 1980s by some psychiatrists to assist in the treatment of PTSD.
Research
Research into the use of MDMA as a therapeutic agent ceased in the mid-1980s when the USA made the drug illegal, largely due to increased police seizures of streets drugs intended for use in recreational settings.
Clinical Trials
Two multi-national Phase 3 clinical trials for MDMA-assisted PTSD treatment have been successful, serving as the last step prior to a request for authorization for MDMA-Assisted Psychotherapy in the US. An FDA decision is anticipated as early as H2 2024.
PTSD Treatment
About 7 or 8 out of every 100 people (or 7-8% of the population) will have PTSD at some point in their lives. About 8 million adults in the US have PTSD during a given year. This is only a small portion of those who have gone through a trauma.
Clinical Trial Use
MDMA for clinical trial use is produced to a strict pharmaceutical standard. A regulated dose is administered in a controlled setting by trained health professionals for specific conditions only.
*The efficacy and safety of MDMA-assisted therapy are currently under investigation. MDMA has not yet been approved by Health Canada or any other regulatory body.*